IOVA · XBRL financial data

Iovance Biotherapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (IOVA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	—	—	1	164	264
Cost of revenue	—	—	—	11	124	173
Research and development	202	259	295	344	282	300
General and administrative	60	84	104	107	153	152
Total operating expenses	262	343	399	—	—	—
Operating income (loss)	(262)	(343)	(399)	(461)	(395)	(403)
Interest income	2	0	3	13	20	10
Income tax expense (benefit)	0	0	0	(3)	(3)	(2)
Net income (loss)	(260)	(342)	(396)	(444)	(372)	(391)
Earnings per share, basic USD per share	(1.88)	(2.23)	(2.49)	(1.89)	(1.28)	(1.09)
Earnings per share, diluted USD per share	(1.88)	(2.23)	(2.49)	(1.89)	(1.28)	(1.09)
Weighted average shares, basic millions of shares	0	0	0	0	0	0
Weighted average shares, diluted millions of shares	0	0	0	0	0	0

Fiscal years (IOVA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	67	78	232	115	116	163
Short-term investments	562	426	240	165	208	134
Marketable securities	562	426	240	165	208	134
Marketable securities, non-current	—	92	—	—	—	—
Accounts receivable	—	—	—	0	69	82
Inventory	—	—	—	10	52	52
Prepaid and other current assets	7	4	7	17	12	12
Total current assets	636	508	479	308	457	443
Property and equipment, net	59	101	105	114	109	131
Right-of-use asset	55	69	73	63	55	46
Total assets	768	777	664	780	910	913
Accounts payable	14	27	27	33	28	22
Accrued liabilities	35	57	52	69	82	111
Total current liabilities	55	89	91	110	122	138
Lease liability, non-current	45	65	72	67	44	44
Total liabilities	112	156	164	196	200	215
Accumulated deficit	(830)	(1,172)	(1,568)	(2,012)	(2,385)	(2,776)
Total stockholders' equity	656	622	500	585	710	699
Total liabilities and equity	768	777	664	780	910	913
Common shares outstanding (cover page) millions of shares	147	157	224	279	328	412

Fiscal years (IOVA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(260)	(342)	(396)	(444)	(372)	(391)
Stock-based compensation	41	70	84	63	110	62
Depreciation and amortization	1	3	9	12	12	13
Net cash from operating activities	(205)	(228)	(293)	(362)	(353)	(302)
Purchases of property and equipment	47	38	20	22	11	34
Net cash from investing activities	(318)	0	256	(155)	(96)	47
Proceeds from issuing common stock	567	203	190	463	397	306
Proceeds from long-term debt	—	1	—	—	—	—
Net cash from financing activities	576	239	190	463	391	301
Net change in cash	—	11	154	(57)	(59)	47

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Iovance Biotherapeutics	111	99	(61)*	453.0M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Elite Pharmaceuticals	39	32	10	1.1B	—	Q1 FY27 10-QJun 30, 2026
Opko Health	384	65	(36)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026
Savara	42	not reported	(30)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Xencor	60	117	2.6*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Dynavax Technologies	160	95	34*	117.4M	—	Q3 FY25 10-QSep 30, 2025
Evolus	42	78	(1.9)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
KalVista Pharmaceuticals	214	41	(14)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
Kura Oncology	70	21	(63)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.